Nasdaq

Ventyx Biosciences Reports Positive Phase 2a Study Results for VTX3232 in Early-Stage Parkinson's Disease

Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease. The study ...
Seeking Alpha

Rapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028

Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinic ...

Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated ...

FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...
Morningstar

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder

SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound ...